Ototoxicity of Long-Term α-Difluoromethylornithine for Skin Cancer Prevention.

ABSTRACT:

Objective

Evaluate the effects of α-difluoromethylornithine (DFMO) on hearing thresholds as part of a randomized, double-blind, placebo-controlled trial.

Methods

Subjects were randomized and assigned to the control (placebo) or experimental (DFMO) group. DFMO or placebo were administered orally (500 mg/m² /day) for up to 5 years.

Results

Subjects taking DFMO had, on average, increased hearing thresholds from baseline across the frequency range compared to subjects in the control group. Statistical analysis revealed this was significant in the lower frequency range.

Conclusions

This randomized controlled trial revealed the presence of increased hearing thresholds associated with long-term DFMO use. As a whole, DFMO may help prevent and treat certain t

SUBMITTER: Chow CL 

PROVIDER: S-EPMC9701242 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature